Li K, et al. - Researchers used the National Health Insurance Research Database 2000–2010 to assess the link between the use of statins and/or metformin and survival outcomes in Taiwanese patients with prostate cancer. Participants included 567 patients in whom prostate cancer had been newly diagnosed and who also had hyperlipidemia and received radiotherapy. They also performed univariate and multivariate Cox regression analyses. Compared with patients who persistently used or used the medicines prior to cancer diagnosis, longer average survival times (9.3 years vs 8.1 years, respectively) were observed in patients who used statins or metformin after prostate cancer diagnosis. In addition, the investigators observed a lower risk of mortality in significant correlation with the use of statins after cancer diagnosis vs no use of statins during the study period. Compared with patients who did not use metformin during the study period, an increased risk of mortality was noted in significant association with the use of metformin after cancer diagnosis. Overall, increased survival in patients with hyperlipidemia and radiotherapy could be achieved by using statins and metformin after prostate cancer diagnosis.